Phase II Trial of REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary & Follicular Thyroid Carcinomas
Phase: PHASE2
Conditions: Thyroid Neoplasms
Sponsor: Kenneth Ain

PROTOCOL AND STATISTICAL ANALYSIS PLAN 
 
 Study Title: REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and 
Follicular Thyroid Carcinoma 
Institution/Site:  
University of Kentucky 
Document (Approval/Update) Date: 
09-21-2008 
NCT Number: 
NCT00287287 
IRB Number 
05-701-F3R 
Coversheet created: 
05-28-2020